Intellectual Property India Publishes Patent Application for 'Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof' Filed by Pfizer Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202518089701 A) filed by Pfizer Inc., New York, on Sept. 19, for 'immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof.'

Inventor(s) include Cooper, David; Emini, Emilio Anthony; Gu, Jianxin; Han, Mingming; Jansen, Kathrin Ute; Kainthan, Rajesh Kumar; Kim, Jin-Hwan; Prasad, Avvari Krishna; Pride, Michael William; Watson, Wendy Jo; and Yang, Yu-Ying.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to 5 new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or 10 Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions."

The patent application was internationally filed on Jan. 15, 2015, under International application No.PCT/IB2015/050315.

Disclaimer: Curated by HT Syndication.